JPH1149684A - Climacteric skin lotion - Google Patents
Climacteric skin lotionInfo
- Publication number
- JPH1149684A JPH1149684A JP9227428A JP22742897A JPH1149684A JP H1149684 A JPH1149684 A JP H1149684A JP 9227428 A JP9227428 A JP 9227428A JP 22742897 A JP22742897 A JP 22742897A JP H1149684 A JPH1149684 A JP H1149684A
- Authority
- JP
- Japan
- Prior art keywords
- weight
- parts
- skin
- malt
- polyacrylic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006210 lotion Substances 0.000 title abstract description 4
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims abstract description 32
- 238000002360 preparation method Methods 0.000 claims abstract description 26
- 239000002537 cosmetic Substances 0.000 claims abstract description 25
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 13
- 150000003839 salts Chemical class 0.000 claims abstract description 13
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 claims abstract description 11
- 239000004584 polyacrylic acid Substances 0.000 claims abstract description 11
- 230000009471 action Effects 0.000 claims abstract description 9
- 230000017531 blood circulation Effects 0.000 claims abstract description 6
- 230000009245 menopause Effects 0.000 claims description 16
- 102000008186 Collagen Human genes 0.000 claims description 4
- 108010035532 Collagen Proteins 0.000 claims description 4
- 229920001436 collagen Polymers 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 230000037303 wrinkles Effects 0.000 abstract description 13
- 235000007340 Hordeum vulgare Nutrition 0.000 abstract description 6
- 230000037319 collagen production Effects 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 2
- 238000006116 polymerization reaction Methods 0.000 abstract description 2
- 240000005979 Hordeum vulgare Species 0.000 abstract 1
- 238000013329 compounding Methods 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 24
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 24
- 239000000686 essence Substances 0.000 description 21
- 239000000839 emulsion Substances 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 18
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 16
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 16
- 235000011069 sorbitan monooleate Nutrition 0.000 description 16
- 239000001593 sorbitan monooleate Substances 0.000 description 16
- 229940035049 sorbitan monooleate Drugs 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000000203 mixture Substances 0.000 description 13
- 206010040954 Skin wrinkling Diseases 0.000 description 12
- 235000019437 butane-1,3-diol Nutrition 0.000 description 12
- 235000011187 glycerol Nutrition 0.000 description 12
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 10
- 238000007665 sagging Methods 0.000 description 10
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 10
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 9
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 9
- 235000019441 ethanol Nutrition 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 235000010445 lecithin Nutrition 0.000 description 9
- 239000000787 lecithin Substances 0.000 description 9
- 229940067606 lecithin Drugs 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 235000019487 Hazelnut oil Nutrition 0.000 description 8
- 229920002385 Sodium hyaluronate Polymers 0.000 description 8
- 239000010468 hazelnut oil Substances 0.000 description 8
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 8
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 8
- 229960002216 methylparaben Drugs 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 229940010747 sodium hyaluronate Drugs 0.000 description 8
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 8
- -1 alkali metal salts Chemical class 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 241000209219 Hordeum Species 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- 230000006872 improvement Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010040880 Skin irritation Diseases 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 241000209140 Triticum Species 0.000 description 3
- 235000021307 Triticum Nutrition 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- 150000005846 sugar alcohols Polymers 0.000 description 3
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 2
- 244000075850 Avena orientalis Species 0.000 description 2
- 235000007319 Avena orientalis Nutrition 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical compound CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000002657 hormone replacement therapy Methods 0.000 description 2
- TZIHFWKZFHZASV-UHFFFAOYSA-N methyl formate Chemical compound COC=O TZIHFWKZFHZASV-UHFFFAOYSA-N 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 2
- 229940055577 oleyl alcohol Drugs 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical class CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 235000007558 Avena sp Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VIZORQUEIQEFRT-UHFFFAOYSA-N Diethyl adipate Chemical compound CCOC(=O)CCCCC(=O)OCC VIZORQUEIQEFRT-UHFFFAOYSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000017657 Menopausal disease Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000010528 free radical solution polymerization reaction Methods 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229950004354 phosphorylcholine Drugs 0.000 description 1
- PYJNAPOPMIJKJZ-UHFFFAOYSA-N phosphorylcholine chloride Chemical compound [Cl-].C[N+](C)(C)CCOP(O)(O)=O PYJNAPOPMIJKJZ-UHFFFAOYSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- CHWRSCGUEQEHOH-UHFFFAOYSA-N potassium oxide Chemical compound [O-2].[K+].[K+] CHWRSCGUEQEHOH-UHFFFAOYSA-N 0.000 description 1
- 229910001950 potassium oxide Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は、更年期の人が用い
るのに好適な、皮膚外用剤に関する。The present invention relates to an external preparation for skin suitable for use by menopausal persons.
【0002】[0002]
【従来の技術】近年、平均寿命が著しく延び、高齢化社
会の到来が告げられており、社会全体に於いて、高齢化
社会に対応したシステムや商品づくりが為されている。
例えば、建物などに於いてはスロープなどが設置され、
車椅子等に対応できるようになってきているし、医薬品
に於いては、更年期のホルモン補充療法用の各種薬剤が
開発されている。この様な対応の中で特に早急な対応が
要求されているのは、シワやくすみを中心とする、皮膚
の更年期に於ける変化への対策である。これは閉経後の
更年期に於いては、かかるシワ、たるみ、くすみ等の皮
膚の諸変化が急激に現れ、ひどい場合には著しい容貌の
変化までももたらしてしまい、これらのことが心理的な
ストレスとなり、更に更年期障害を増悪する場合が少な
からずあるからである。この様な皮膚形態、容貌の変化
が防げれば、更年期障害に於ける心理的なストレスを少
なからず軽減できるため、この様な作用を有する処置組
成物の開発が強く望まれていた。取り分け、手軽に処置
しうる皮膚外用剤形態のものが望まれていた。2. Description of the Related Art In recent years, the average life expectancy has been remarkably prolonged, and the arrival of an aging society has been announced. In the whole society, systems and products corresponding to the aging society have been produced.
For example, slopes are installed in buildings,
Wheelchairs and the like are becoming available, and in medicine, various drugs for menopausal hormone replacement therapy are being developed. Among such measures, a particularly urgent need is to take measures against changes in the skin during menopause, mainly wrinkles and dullness. In menopause after menopause, various changes in the skin such as wrinkles, sagging, dullness, etc. appear rapidly, and in severe cases, they also bring about remarkable changes in appearance, and these are psychological stresses. This is because there are many cases where the menopause is worsened. If such changes in skin morphology and appearance can be prevented, psychological stress in menopausal disorders can be alleviated to a considerable extent, and there has been a strong demand for the development of a treatment composition having such effects. In particular, a skin external preparation that can be easily treated has been desired.
【0003】一方、麦芽のエッセンス、ポリアクリル酸
とその塩、γ−オリザノール等は広く化粧料や皮膚外用
医薬品等の皮膚外用剤の分野で用いられている原料では
あるが、これらを組み合わせて用いることは全く知られ
ていなかったし、これらを組み合わせて用いることによ
り、上記更年期用に好適な皮膚外用剤が得られることも
全く知られていなかった。更にこの様な原料を含む化粧
料が更年期のシワ、たるみ、くすみの改善に好適である
ことも全く知られていなかった。On the other hand, malt essence, polyacrylic acid and its salts, γ-oryzanol and the like are widely used in the field of external preparations for skin such as cosmetics and external preparations for skin, but they are used in combination. It was not known at all, nor was it known that the use of these in combination would provide a skin external preparation suitable for the above menopause. Furthermore, it has not been known at all that cosmetics containing such raw materials are suitable for improvement of wrinkles, sagging and dullness in menopause.
【0004】[0004]
【発明が解決しようとする課題】本発明はこの様な状況
下為されたものであり、シワ、たるみ、くすみ等が著し
く発現する更年期に好適な、皮膚外用剤を提供すること
を課題とする。SUMMARY OF THE INVENTION The present invention has been made under such circumstances, and it is an object of the present invention to provide a skin external preparation suitable for menopause, in which wrinkles, sagging, dullness, etc. are remarkably exhibited. .
【0005】[0005]
【課題の解決手段】かかる状況に鑑みて、本発明者らは
シワ、たるみ、くすみ等が著しく発現する更年期に好適
な、皮膚外用剤を求めて鋭意研究を重ねた結果、麦芽の
エッセンスとポリアクリル酸及び/又は生理的に許容さ
れるその塩とを含有することを特徴とする、皮膚外用剤
にその様な作用を見いだし、発明を完成させるに至っ
た。以下、本発明について実施の形態を中心に詳細に説
明を加える。In view of this situation, the present inventors have conducted intensive studies in search of an external preparation for skin suitable for menopause in which wrinkles, sagging, dullness, etc. remarkably appear. Such action was found in a skin external preparation characterized by containing acrylic acid and / or a physiologically acceptable salt thereof, and the present invention was completed. Hereinafter, the present invention will be described in detail focusing on embodiments.
【0006】[0006]
(1)更年期に於ける皮膚の形態・生理変化 上述した様に、更年期に於いては、皮膚は形態的或いは
生理的に大きく変化する。その特徴は、シワ、たるみ、
くすみ等の皮膚の諸変化が急激に現れ、ひどい場合には
著しい容貌の変化までももたらしてしまうことである。
これは男女問わずに現れる現象であり、この原因として
考えられているのは、更年期に於ける著しいエストロゲ
ン・プロゲステロン・アンドロゲン等のホルモンバラン
スの変調と言われている。これらはホルモン補充療法に
よりかなりの部分の予防が可能であるが、一度生じてし
まったシワやタルミを改善するには充分といえず、又、
くすみに対してはあまり効果があるとは言えなかった。
この様な変化の形態的な特徴として捉えられていること
は、皮膚に於いては真皮コラーゲン線維束に乱れが生じ
ており、コラーゲンそのものの保水能力も著しく減少し
ていること、さらにコラーゲン生成能力も低下している
こと、血行、取り分け末梢の毛細血管に於ける血行が阻
害されており、新陳代謝の速度が低下していること等が
本発明者らによって明らかにされた。(1) Changes in skin morphology and physiology during menopause As described above, skin changes significantly morphologically or physiologically during menopause. Its characteristics are wrinkles, sagging,
Various changes of the skin such as dullness suddenly appear, and in severe cases, even a remarkable change in appearance.
This is a phenomenon that appears regardless of gender, and the cause is considered to be a remarkable modulation of hormonal balance of estrogen, progesterone and androgen during menopause. These can be prevented to a large extent by hormone replacement therapy, but they are not enough to remedy wrinkles and tarmi that have occurred once.
It was not very effective against dullness.
The morphological features of such changes are that the dermal collagen fiber bundles are disrupted in the skin, the water retention capacity of collagen itself is significantly reduced, and the collagen production capacity The present inventors have found that the blood circulation, particularly blood circulation in peripheral capillaries is inhibited, and the metabolic rate is reduced.
【0007】(2)本発明で用いる麦芽のエッセンス 本発明の麦芽のエッセンスは、麦を発芽させて得られた
麦芽のエッセンスであり、麦の種類としては、小麦、大
麦、燕麦何れも使用が可能であるが、大麦が最も好まし
い。本発明で言うエッセンスとは、麦芽そのもの、麦芽
を乾燥、細切、粉砕した加工物、麦芽を圧搾して得た圧
搾物、麦芽そのもの或いは加工物に溶媒を加えて抽出し
た抽出物とその溶媒除去物、圧搾物、抽出物、抽出物の
溶媒除去物をカラムクロマトグラフィーや液液抽出等で
分画精製した精製物とその溶媒除去物等の総称を意味
し、これらの内では抽出物及びその溶媒除去物が特に好
ましい。抽出は、常法に従って行えば良く、例えば、
水、エタノール、メタノール、1,3−ブタンジオール
等のアルコール類、アセトン、メチルエチルケトン等の
ケトン類、ジエチルエーテル、テトラヒドロフラン等の
エーテル類、塩化メチレン、クロロホルム等のハロゲン
化炭化水素類、アセトニトリル、アクリロニトリル等の
ニトリル類、酢酸エチル、蟻酸メチル等のエステル類か
ら選ばれる1種乃至は2種以上を1〜10倍量加え、室
温であれば数日、沸点付近の温度であれば数時間浸漬す
ればよい。抽出物の内好ましいものはアルコール抽出物
である。中でも1,3−ブタンジオール、グリセリン、
プロピレングリコール、ポリエチレングリコールなどの
多価アルコール抽出物が特に好ましい。本発明に於ける
これら麦芽エッセンスの好ましい含有量は、皮膚外用剤
全量に対して、0.01〜10重量%であり、より好ま
しくは0.05〜7重量%であり、更に好ましくは0.
1〜5重量%である。 (製造例1)大麦の麦芽1Kgに1,3−ブタンジオー
ル5lを加え、80℃で3時間加熱攪拌し、冷却して濾
過して不溶物を除き麦芽エッセンス1を得た。 (製造例2)大麦の麦芽1Kgにエタノール5lを加
え、加熱環流し濾過して不溶物を除いた後減圧溜去しエ
ッセンス2を得た。 (製造例3)小麦の麦芽1Kgにエタノール5lを加
え、加熱環流し濾過して不溶物を除いた後減圧溜去しエ
ッセンス3を得た。 (製造例4)燕麦の麦芽1Kgにエタノール5lを加
え、加熱環流し濾過して不溶物を除いた後減圧溜去しエ
ッセンス4を得た。(2) Essence of malt used in the present invention The essence of malt of the present invention is an essence of malt obtained by germinating wheat, and any of wheat, barley and oat may be used. Although possible, barley is most preferred. The essence referred to in the present invention is malt itself, malt dried, shredded, pulverized processed product, pressed product obtained by pressing malt, malt itself or an extract extracted by adding a solvent to the processed product and its solvent. Removed products, squeezed products, extracts, extracts, solvent removal of the extract is a generic term for purified products obtained by fractionation and purification by column chromatography, liquid-liquid extraction, etc. and their solvent removal products, etc. The solvent removed is particularly preferred. The extraction may be performed according to a conventional method.
Water, alcohols such as ethanol, methanol and 1,3-butanediol, ketones such as acetone and methyl ethyl ketone, ethers such as diethyl ether and tetrahydrofuran, halogenated hydrocarbons such as methylene chloride and chloroform, acetonitrile, acrylonitrile and the like 1 to 10 times the amount of one or more selected from esters such as nitriles, ethyl acetate, methyl formate, etc., and immerse for several days at room temperature and several hours at a temperature near the boiling point. Good. Preferred among the extracts are alcohol extracts. Among them, 1,3-butanediol, glycerin,
Polyhydric alcohol extracts such as propylene glycol and polyethylene glycol are particularly preferred. The preferred content of these malt essences in the present invention is 0.01 to 10% by weight, more preferably 0.05 to 7% by weight, and even more preferably 0.1 to 10% by weight, based on the total amount of the external preparation for skin.
1 to 5% by weight. (Production Example 1) To 1 kg of malt of barley was added 5 l of 1,3-butanediol, and the mixture was heated and stirred at 80 ° C for 3 hours, cooled and filtered to remove insolubles, thereby obtaining malt essence 1. (Production Example 2) Ethanol 2 was obtained by adding 5 l of ethanol to 1 kg of barley malt, heating under reflux and filtering to remove insolubles, and distilling under reduced pressure. (Production Example 3) To 1 kg of malt of wheat was added 5 l of ethanol, and the mixture was heated under reflux and filtered to remove insolubles. (Production Example 4) To 1 kg of malt of oats was added 5 l of ethanol, and the mixture was heated under reflux and filtered to remove insolubles.
【0008】(3)本発明で用いるポリアクリル酸及び
/又は生理的に許容されるその塩 本発明で用いるポリアクリル酸及び/又は生理的に許容
されるその塩の、ポリアクリル酸部分としては、重合度
10〜100000のものが好ましく、これらは既に市
販されているし、例えば、溶液重合法等の常法に従って
製造することもできる。これらの生理的に許容される塩
としては、例えば、カリウム、ナトリウム等のアルカリ
金属塩、カルシウム、マグネシウム等のアルカリ土類金
属塩、アンモニウム塩、リジンやアルギニンなどの塩基
性アミノ酸塩、トリエタノールアミンやトリエチルアミ
ン等の有機アミン塩等が好適に例示できる。本発明皮膚
外用剤に於けるポリアクリル酸及び/又は生理的に許容
されるその塩の好ましい含有量は、0.01〜10重量
%であり、より好ましくは0.05〜7重量%であり、
更に好ましくは0.1〜5重量%である。(3) The polyacrylic acid used in the present invention and / or a physiologically acceptable salt thereof The polyacrylic acid portion of the polyacrylic acid and / or a physiologically acceptable salt thereof used in the present invention includes: The polymerization degree is preferably from 10 to 100,000, and these are already commercially available, and can be produced according to a conventional method such as a solution polymerization method. Examples of these physiologically acceptable salts include alkali metal salts such as potassium and sodium, alkaline earth metal salts such as calcium and magnesium, ammonium salts, basic amino acid salts such as lysine and arginine, and triethanolamine. And organic amine salts such as triethylamine. The preferred content of polyacrylic acid and / or a physiologically acceptable salt thereof in the external preparation for skin of the present invention is 0.01 to 10% by weight, more preferably 0.05 to 7% by weight. ,
More preferably, it is 0.1 to 5% by weight.
【0009】(4)本発明の皮膚外用剤 本発明の皮膚外用剤は上記麦芽のエッセンスとポリアク
リル酸及び/又は生理的に許容されるその塩とを含有す
ることを特徴とする。又、本発明の皮膚外用剤の特徴と
する作用は、血行を促進し、コラーゲン生成を促進し
て、シワ、たるみ、くすみを改善することである。取り
分け、更年期の閉経後に生じるこの様な現象に対して有
効に作用する。本発明の皮膚外用剤としては、化粧水、
乳液、クリーム、ファンデーション、パック等の化粧
料、軟膏、クリーム、液剤、貼付剤などの皮膚外用医薬
組成物などが好ましく例示できる。このうち最も好まし
い形態は、毎日使用できる化粧料である。これは本発明
の皮膚外用剤が安全性に優れるためである。本発明の皮
膚外用剤に於いては、これら必須成分以外に、血行促進
作用とコラーゲン生成作用を促進する、γ−オリザノー
ルを含有することが特に好ましい。γ−オリザノールの
好ましい含有量は、0.001〜1重量%、より好まし
くは0.005〜0.5重量%であり、更に好ましくは
0.01〜0.1重量%である。その他、本発明の皮膚
外用剤に含有することが好ましい成分としては、例え
ば、ヒアルロン酸の塩、多硫酸化多糖類の塩、硫酸化多
糖類の塩、レシチン、ホスファチジルエタノールアミ
ン、ホスファチジルイノシトール、メタクリロイルオキ
シエチルホスホリルコリンをモノマー又はモノマーの1
つとする重合体又は共重合体等のホスホリピッド等の保
湿性を維持する作用に優れる物質を含有するのが好まし
い。これら保湿性物質の好ましい含有量は、0.1〜2
0重量%であり、より好ましくは0.2〜10重量%で
あり、更に好ましくは0.5〜5重量%である。これら
の成分以外に本発明の皮膚外用剤は、通常皮膚外用剤で
使用されている任意成分を含有することができる。この
様な任意成分としては、例えば、ワセリンやマイクロク
リスタリンワックス等のような炭化水素類、ホホバ油や
ゲイロウ等のエステル類、牛脂、オリーブ油等のトリグ
リセライド類、セタノール、オレイルアルコール等の高
級アルコール類、ステアリン酸、オレイン酸等の脂肪
酸、グリセリンや1,3−ブタンジオール等の多価アル
コール類、非イオン界面活性剤、アニオン界面活性剤、
カチオン界面活性剤、両性界面活性剤、エタノール、カ
ーボポール等の増粘剤、防腐剤、紫外線吸収剤、抗酸化
剤、色素、粉体類等が例示できる。尚、ここで留意する
ことは更年期に於いては皮膚機能が低下するため、界面
活性剤等皮膚刺激性の多いものについては、なるべく皮
膚刺激性の少ない界面活性剤を用いるのが特に好まし
い。従って、アニオン性界面活性剤のように皮膚刺激性
の高い原料を用いずに、皮膚刺激性の低い親水性界面活
性剤を用いるのが好ましい。かかる界面活性剤としては
非イオン性界面活性剤が好ましく、ポリオキシエチレン
ポリオキシプロピレンアルキルエーテルを親水性界面活
性剤として用いるのが好ましい。更に、多価アルコール
として、グリセリンを含有するのが好ましく、含有量と
しても、10〜25重量%、更に好ましくは15〜20
重量%と大量に含有するのが特に好ましい。(4) External preparation for skin of the present invention The external preparation for skin of the present invention is characterized by containing the above malt essence and polyacrylic acid and / or a physiologically acceptable salt thereof. The characteristic action of the external preparation for skin of the present invention is to promote blood circulation, promote collagen production, and improve wrinkles, sagging and dullness. In particular, it works effectively against such phenomena that occur after menopause. As the skin external preparation of the present invention, a lotion,
Preferred examples include cosmetics such as emulsions, creams, foundations and packs, and external skin pharmaceutical compositions such as ointments, creams, solutions and patches. The most preferred form is a cosmetic that can be used every day. This is because the skin external preparation of the present invention is excellent in safety. The external preparation for skin of the present invention particularly preferably contains γ-oryzanol, which promotes blood circulation promoting action and collagen producing action, in addition to these essential components. The preferred content of γ-oryzanol is 0.001 to 1% by weight, more preferably 0.005 to 0.5% by weight, and still more preferably 0.01 to 0.1% by weight. Other components preferably contained in the external preparation for skin of the present invention include, for example, salts of hyaluronic acid, salts of polysulfated polysaccharides, salts of sulfated polysaccharides, lecithin, phosphatidylethanolamine, phosphatidylinositol, methacryloyl. Oxyethyl phosphorylcholine is a monomer or one of the monomers
It is preferable to contain a substance having an excellent action of maintaining moisture retention, such as a phospholipid such as a polymer or a copolymer. The preferred content of these moisturizing substances is 0.1 to 2
0% by weight, more preferably 0.2 to 10% by weight, still more preferably 0.5 to 5% by weight. In addition to these components, the external preparation for skin of the present invention can contain optional components usually used in external preparations for skin. Such optional components include, for example, hydrocarbons such as petrolatum and microcrystalline wax, esters such as jojoba oil and gay wax, triglycerides such as tallow, olive oil, higher alcohols such as cetanol and oleyl alcohol, Stearic acid, fatty acids such as oleic acid, polyhydric alcohols such as glycerin and 1,3-butanediol, nonionic surfactants, anionic surfactants,
Examples include cationic surfactants, amphoteric surfactants, thickeners such as ethanol and carbopol, preservatives, ultraviolet absorbers, antioxidants, dyes, and powders. It should be noted here that since the skin function is deteriorated in the climacteric period, it is particularly preferable to use a surfactant having high skin irritation such as a surfactant as much as possible. Therefore, it is preferable to use a hydrophilic surfactant having low skin irritation without using a raw material having high skin irritation such as an anionic surfactant. As such a surfactant, a nonionic surfactant is preferable, and polyoxyethylene polyoxypropylene alkyl ether is preferably used as a hydrophilic surfactant. Further, glycerin is preferably contained as a polyhydric alcohol, and the content is also 10 to 25% by weight, more preferably 15 to 20% by weight.
It is particularly preferable to contain a large amount by weight.
【0010】[0010]
【実施例】以下に、本発明について実施例を挙げて詳細
に説明するが、本発明がこれら実施例にのみ限定を受け
ないことは言うまでもない。EXAMPLES Hereinafter, the present invention will be described in detail with reference to examples, but it goes without saying that the present invention is not limited only to these examples.
【0011】<実施例1>下記に示す処方で乳液(化粧
料)を作成した。即ち、イ、ロをそれぞれ80℃に加熱
し溶解させ、イにロを徐々に加え乳化し、攪拌冷却して
乳液(化粧料)を得た。 イ ヘーゼルナッツオイル 0.5重量部 ソルビタンモノオレート 0.1重量部 POE(20)ソルビタンモノオレート 0.1重量部 POE(34)POP(23)ラウリルエーテル 0.1重量部 レシチン 2 重量部 ロ 1,3−ブタンジオール 10 重量部 グリセリン 20 重量部 麦芽エッセンス1 1 重量部 ポリアクリル酸ナトリウム 5 重量部 ヒアルロン酸ナトリウム 0.1重量部 メチルパラベン 0.3重量部 水 60.8重量部Example 1 An emulsion (cosmetic) was prepared according to the following formulation. That is, (a) and (b) were each heated and dissolved at 80 ° C., (b) was gradually added to (a), emulsified, and cooled by stirring to obtain an emulsion (cosmetic). A Hazelnut oil 0.5 parts by weight Sorbitan monooleate 0.1 parts by weight POE (20) Sorbitan monooleate 0.1 parts by weight POE (34) POP (23) Lauryl ether 0.1 parts by weight Lecithin 2 parts by weight b 1, 3-butanediol 10 parts by weight Glycerin 20 parts by weight Malt essence 11 1 part by weight Sodium polyacrylate 5 parts by weight Sodium hyaluronate 0.1 part by weight Methyl paraben 0.3 parts by weight Water 60.8 parts by weight
【0012】<実施例2>下記に示す処方で乳液(化粧
料)を作成した。即ち、イ、ロをそれぞれ80℃に加熱
し溶解させ、イにロを徐々に加え乳化し、攪拌冷却して
乳液(化粧料)を得た。 イ ヘーゼルナッツオイル 0.5重量部 ソルビタンモノオレート 0.1重量部 POE(20)ソルビタンモノオレート 0.1重量部 POE(34)POP(23)ラウリルエーテル 0.1重量部 レシチン 2 重量部 ロ 1,3−ブタンジオール 10 重量部 グリセリン 20 重量部 麦芽エッセンス2 1 重量部 ポリアクリル酸ナトリウム 5 重量部 ヒアルロン酸ナトリウム 0.1重量部 メチルパラベン 0.3重量部 水 60.8重量部Example 2 An emulsion (cosmetic) was prepared according to the following formulation. That is, (a) and (b) were each heated and dissolved at 80 ° C., (b) was gradually added to (a), emulsified, and cooled by stirring to obtain an emulsion (cosmetic). A Hazelnut oil 0.5 parts by weight Sorbitan monooleate 0.1 parts by weight POE (20) Sorbitan monooleate 0.1 parts by weight POE (34) POP (23) Lauryl ether 0.1 parts by weight Lecithin 2 parts by weight b 1, 3-butanediol 10 parts by weight Glycerin 20 parts by weight Malt essence 21 1 part by weight Sodium polyacrylate 5 parts by weight Sodium hyaluronate 0.1 part by weight Methyl paraben 0.3 parts by weight Water 60.8 parts by weight
【0013】<実施例3>下記に示す処方で乳液(化粧
料)を作成した。即ち、イ、ロをそれぞれ80℃に加熱
し溶解させ、イにロを徐々に加え乳化し、攪拌冷却して
乳液(化粧料)を得た。 イ ヘーゼルナッツオイル 0.5重量部 ソルビタンモノオレート 0.1重量部 POE(20)ソルビタンモノオレート 0.1重量部 POE(34)POP(23)ラウリルエーテル 0.1重量部 レシチン 2 重量部 ロ 1,3−ブタンジオール 10 重量部 グリセリン 20 重量部 麦芽エッセンス3 1 重量部 ポリアクリル酸ナトリウム 5 重量部 ヒアルロン酸ナトリウム 0.1重量部 メチルパラベン 0.3重量部 水 60.8重量部Example 3 An emulsion (cosmetic) was prepared according to the following formulation. That is, (a) and (b) were each heated and dissolved at 80 ° C., (b) was gradually added to (a), emulsified, and cooled by stirring to obtain an emulsion (cosmetic). A Hazelnut oil 0.5 parts by weight Sorbitan monooleate 0.1 parts by weight POE (20) Sorbitan monooleate 0.1 parts by weight POE (34) POP (23) Lauryl ether 0.1 parts by weight Lecithin 2 parts by weight b 1, 3-butanediol 10 parts by weight Glycerin 20 parts by weight Malt essence 31 1 part by weight Sodium polyacrylate 5 parts by weight Sodium hyaluronate 0.1 part by weight Methyl paraben 0.3 parts by weight Water 60.8 parts by weight
【0014】<実施例4>下記に示す処方で乳液(化粧
料)を作成した。即ち、イ、ロをそれぞれ80℃に加熱
し溶解させ、イにロを徐々に加え乳化し、攪拌冷却して
乳液(化粧料)を得た。 イ ヘーゼルナッツオイル 0.5重量部 ソルビタンモノオレート 0.1重量部 POE(20)ソルビタンモノオレート 0.1重量部 POE(34)POP(23)ラウリルエーテル 0.1重量部 レシチン 2 重量部 ロ 1,3−ブタンジオール 10 重量部 グリセリン 20 重量部 麦芽エッセンス4 1 重量部 ポリアクリル酸ナトリウム 5 重量部 ヒアルロン酸ナトリウム 0.1重量部 メチルパラベン 0.3重量部 水 60.8重量部Example 4 An emulsion (cosmetic) was prepared according to the following formulation. That is, (a) and (b) were each heated and dissolved at 80 ° C., (b) was gradually added to (a), emulsified, and cooled by stirring to obtain an emulsion (cosmetic). A Hazelnut oil 0.5 parts by weight Sorbitan monooleate 0.1 parts by weight POE (20) Sorbitan monooleate 0.1 parts by weight POE (34) POP (23) Lauryl ether 0.1 parts by weight Lecithin 2 parts by weight b 1, 3-butanediol 10 parts by weight Glycerin 20 parts by weight Malt essence 41 1 part by weight Sodium polyacrylate 5 parts by weight Sodium hyaluronate 0.1 parts by weight Methyl paraben 0.3 parts by weight Water 60.8 parts by weight
【0015】<実施例5>下記に示す処方で乳液(化粧
料)を作成した。即ち、イ、ロをそれぞれ80℃に加熱
し溶解させ、イにロを徐々に加え乳化し、攪拌冷却して
乳液(化粧料)を得た。 イ ヘーゼルナッツオイル 0.5重量部 ソルビタンモノオレート 0.1重量部 POE(20)ソルビタンモノオレート 0.1重量部 POE(34)POP(23)ラウリルエーテル 0.1重量部 レシチン 2 重量部 γ−オリザノール 0.5重量部 ロ 1,3−ブタンジオール 10 重量部 グリセリン 20 重量部 麦芽エッセンス1 1 重量部 ポリアクリル酸ナトリウム 5 重量部 ヒアルロン酸ナトリウム 0.1重量部 メチルパラベン 0.3重量部 水 60.3重量部Example 5 An emulsion (cosmetic) was prepared according to the following formulation. That is, (a) and (b) were each heated and dissolved at 80 ° C., (b) was gradually added to (a), emulsified, and cooled by stirring to obtain an emulsion (cosmetic). A Hazelnut oil 0.5 parts by weight Sorbitan monooleate 0.1 parts by weight POE (20) Sorbitan monooleate 0.1 parts by weight POE (34) POP (23) lauryl ether 0.1 parts by weight Lecithin 2 parts by weight γ-oryzanol 0.5 parts by weight b 1,3-butanediol 10 parts by weight glycerin 20 parts by weight Malt essence 1 1 part by weight Sodium polyacrylate 5 parts by weight Sodium hyaluronate 0.1 part by weight Methyl paraben 0.3 parts by weight Water 60.3 Parts by weight
【0016】<実施例6>下記に示す処方で乳液(化粧
料)を作成した。即ち、イ、ロをそれぞれ80℃に加熱
し溶解させ、イにロを徐々に加え乳化し、攪拌冷却して
乳液(化粧料)を得た。 イ ヘーゼルナッツオイル 0.5重量部 ソルビタンモノオレート 0.1重量部 POE(20)ソルビタンモノオレート 0.1重量部 POE(34)POP(23)ラウリルエーテル 0.1重量部 レシチン 2 重量部 γ−オリザノール 0.5重量部 ロ 1,3−ブタンジオール 10 重量部 グリセリン 20 重量部 麦芽エッセンス1 1 重量部 ポリアクリル酸ナトリウム 5 重量部 硫酸化トレハロースナトリウム 0.1重量部 メチルパラベン 0.3重量部 水 60.3重量部Example 6 An emulsion (cosmetic) was prepared according to the following formulation. That is, (a) and (b) were each heated and dissolved at 80 ° C., (b) was gradually added to (a), emulsified, and cooled by stirring to obtain an emulsion (cosmetic). A Hazelnut oil 0.5 parts by weight Sorbitan monooleate 0.1 parts by weight POE (20) Sorbitan monooleate 0.1 parts by weight POE (34) POP (23) lauryl ether 0.1 parts by weight Lecithin 2 parts by weight γ-oryzanol 0.5 parts by weight b 1,3-butanediol 10 parts by weight glycerin 20 parts by weight Malt essence 11 1 part by weight Sodium polyacrylate 5 parts by weight Sodium sulfated trehalose 0.1 part by weight Methyl paraben 0.3 parts by weight Water 60. 3 parts by weight
【0017】<実施例7>下記に示す処方で乳液(化粧
料)を作成した。即ち、イ、ロをそれぞれ80℃に加熱
し溶解させ、イにロを徐々に加え乳化し、攪拌冷却して
乳液(化粧料)を得た。 イ ヘーゼルナッツオイル 0.5重量部 ソルビタンモノオレート 0.1重量部 POE(20)ソルビタンモノオレート 0.1重量部 POE(34)POP(23)ラウリルエーテル 0.1重量部 レシチン 2 重量部 γ−オリザノール 1 重量部 ロ 1,3−ブタンジオール 10 重量部 グリセリン 20 重量部 麦芽エッセンス1 1 重量部 ポリアクリル酸ナトリウム 5 重量部 ヒアルロン酸ナトリウム 0.1重量部 メチルパラベン 0.3重量部 水 59.8重量部Example 7 An emulsion (cosmetic) was prepared according to the following formulation. That is, (a) and (b) were each heated and dissolved at 80 ° C., (b) was gradually added to (a), emulsified, and cooled by stirring to obtain an emulsion (cosmetic). A Hazelnut oil 0.5 parts by weight Sorbitan monooleate 0.1 parts by weight POE (20) Sorbitan monooleate 0.1 parts by weight POE (34) POP (23) lauryl ether 0.1 parts by weight Lecithin 2 parts by weight γ-oryzanol 1 part by weight b 1,3-butanediol 10 parts by weight glycerin 20 parts by weight Malt essence 1 1 part by weight Sodium polyacrylate 5 parts by weight Sodium hyaluronate 0.1 part by weight Methyl paraben 0.3 parts by weight Water 59.8 parts by weight
【0018】<実施例8>下記に示す処方で乳液(化粧
料)を作成した。即ち、イ、ロをそれぞれ80℃に加熱
し溶解させ、イにロを徐々に加え乳化し、攪拌冷却して
乳液(化粧料)を得た。 イ ヘーゼルナッツオイル 0.5重量部 ソルビタンモノオレート 0.1重量部 POE(20)ソルビタンモノオレート 0.1重量部 POE(34)POP(23)ラウリルエーテル 0.1重量部 ホスファリジルイノシトール 2 重量部 γ−オリザノール 0.5重量部 ロ 1,3−ブタンジオール 10 重量部 グリセリン 20 重量部 麦芽エッセンス1 1 重量部 ポリアクリル酸ナトリウム 5 重量部 ヒアルロン酸ナトリウム 0.1重量部 メチルパラベン 0.3重量部 水 60.3重量部Example 8 An emulsion (cosmetic) was prepared according to the following formulation. That is, (a) and (b) were each heated and dissolved at 80 ° C., (b) was gradually added to (a), emulsified, and cooled by stirring to obtain an emulsion (cosmetic). A Hazelnut oil 0.5 parts by weight Sorbitan monooleate 0.1 parts by weight POE (20) Sorbitan monooleate 0.1 parts by weight POE (34) POP (23) lauryl ether 0.1 parts by weight Phosphalidyl inositol 2 parts by weight γ-oryzanol 0.5 parts by weight b 1,3-butanediol 10 parts by weight glycerin 20 parts by weight Malt essence 1 1 part by weight Sodium polyacrylate 5 parts by weight Sodium hyaluronate 0.1 part by weight Methyl paraben 0.3 parts by weight Water 60.3 parts by weight
【0019】<実施例9>実施例1〜5の乳液(化粧
料)について、シワ、たるみ、くすみに悩みを抱く、閉
経後の更年期障害を有する女性パネラー1群10名を用
いて、1カ月間の使用テストを行い、本発明の乳液(化
粧料)の作用を調べた。即ち、連日朝晩2回使用しても
らい、シワ、たるみ、くすみの改善をアンケートで回答
してもらった。比較例1として、実施例1のポリアクリ
ル酸ナトリウムを水に置換したものを、比較例2とし
て、実施例1の麦芽エッセンス1を水に置換したものを
用いた。又、対照例として、実施例1のポリアクリル酸
ナトリウムと麦芽エッセンス1とを水に置換したものを
用いた。この結果を回答の評点の平均値(評点3:著し
い改善、評点2:改善、評点1:僅かな改善、評点0:
改善無し)として表1に示す。これより、本発明の乳液
(化粧料)は何れも更年期に於けるシワ、たるみ、くす
みを改善する作用に優れる事が明白である。更に、麦芽
エッセンスとしては大麦の麦芽エッセンスが好ましく、
γ−オリザノールを含有することが好ましいことがわか
る。<Example 9> The emulsions (cosmetics) of Examples 1 to 5 were subjected to 1 month using a group of 10 female panelists with postmenopausal menopause suffering from wrinkles, sagging and dullness. A use test was carried out to examine the effect of the emulsion (cosmetic) of the present invention. In other words, they were used twice a day in the morning and evening, and a questionnaire was given to improve wrinkles, sagging, and dullness. Comparative Example 1 was obtained by replacing sodium polyacrylate of Example 1 with water, and Comparative Example 2 was obtained by replacing malt essence 1 of Example 1 with water. Further, as a control example, a product obtained by replacing the sodium polyacrylate of Example 1 with malt essence 1 with water was used. The results were evaluated as the average value of the scores of the answers (score 3: marked improvement, score 2: improved, score 1: slight improvement, score 0:
(No improvement) is shown in Table 1. From this, it is clear that all the emulsions (cosmetics) of the present invention are excellent in the action of improving wrinkles, sagging and dullness during menopause. Further, as the malt essence, barley malt essence is preferable,
It is understood that it is preferable to contain γ-oryzanol.
【0020】[0020]
【表1】 [Table 1]
【0021】<実施例10>下記に示す処方に従って、
皮膚外用医薬組成物を得た。即ち、イ、ロ、ハそれぞれ
を80℃に加熱可溶化し、イに徐々にロを加え、更にハ
を徐々に加え乳化し、攪拌冷却し皮膚外用医薬組成物を
得た。 イ アジピン酸ジエチル 10 重量部 流動パラフィン 5 重量部 オレイルアルコール 1 重量部 ステアリルモノグリセライド 3 重量部 POE(20)ステアリルエーテル 1 重量部 POE(34)POP(23)ラウリルエーテル 0.1重量部 γ−オリザノール 1 重量部 エストラジオール 1 重量部 レシチン 1 重量部 プロピルパラベン 0.1重量部 ロ カルボキシビニルポリマー 0.2重量部 グリセリン 20 重量部 麦芽エッセンス1 5 重量部 ヒアルロン酸ナトリウム 0.1重量部 水 30 重量部 ハ 水酸化カリウム 0.2重量部 水 20.4重量部Example 10 According to the following formulation,
An external skin pharmaceutical composition was obtained. That is, each of (a), (b) and (c) was heated and solubilized at 80 ° C., (b) was gradually added to (a), and (c) was gradually added and emulsified, followed by stirring and cooling to obtain a skin external pharmaceutical composition. A Diethyl adipate 10 parts by weight Liquid paraffin 5 parts by weight Oleyl alcohol 1 part by weight Stearyl monoglyceride 3 parts by weight POE (20) stearyl ether 1 part by weight POE (34) POP (23) lauryl ether 0.1 part by weight γ-oryzanol 1 Parts by weight estradiol 1 part by weight lecithin 1 part by weight propylparaben 0.1 part by weight b carboxyvinyl polymer 0.2 part by weight glycerin 20 parts by weight malt essence 15 parts by weight sodium hyaluronate 0.1 part by weight water 30 parts by weight c water Potassium oxide 0.2 parts by weight Water 20.4 parts by weight
【0022】[0022]
【発明の効果】本発明によれば、シワ、たるみ、くすみ
等が著しく発現する更年期に好適な、皮膚外用剤を提供
することができる。According to the present invention, it is possible to provide an external preparation for skin which is suitable for menopause when wrinkles, sagging, dullness, etc. are remarkably exhibited.
───────────────────────────────────────────────────── フロントページの続き (72)発明者 荒木 啓光 東京都板橋区舟渡2丁目8番16号 株式会 社科薬開発部内 ──────────────────────────────────────────────────続 き Continued on the front page (72) Inventor Hiromitsu Araki 2-8-16 Funatari, Itabashi-ku, Tokyo
Claims (5)
/又は生理的に許容されるその塩とを含有することを特
徴とする、皮膚外用剤。An external preparation for skin, comprising malt essence and polyacrylic acid and / or a physiologically acceptable salt thereof.
を特徴とする、請求項1に記載の皮膚外用剤。2. The external preparation for skin according to claim 1, further comprising γ-oryzanol.
る、請求項1又は2に記載の皮膚外用剤。3. The external preparation for skin according to claim 1, which is used for menopause.
1〜3の何れか一項に記載の皮膚外用剤。4. The external preparation for skin according to any one of claims 1 to 3, which is a cosmetic.
ラーゲン増成作用を有することを特徴とする、請求項1
〜4の何れか一項に記載の皮膚外用剤。5. The method according to claim 1, which has an action of promoting blood circulation and / or an action of increasing collagen.
5. The external preparation for skin according to any one of items 4 to 4.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9227428A JPH1149684A (en) | 1997-08-08 | 1997-08-08 | Climacteric skin lotion |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9227428A JPH1149684A (en) | 1997-08-08 | 1997-08-08 | Climacteric skin lotion |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH1149684A true JPH1149684A (en) | 1999-02-23 |
Family
ID=16860707
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9227428A Pending JPH1149684A (en) | 1997-08-08 | 1997-08-08 | Climacteric skin lotion |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH1149684A (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20010092070A (en) * | 2000-03-20 | 2001-10-24 | 유상옥,송운한 | Skin elasticity-improving cosmetic composition comprising Chestnut inner bark extract and Malt extract |
JP2002097149A (en) * | 2000-09-20 | 2002-04-02 | Noevir Co Ltd | Skin care preparation |
JP2002104952A (en) * | 2000-09-28 | 2002-04-10 | Noevir Co Ltd | Skin case preparation |
KR100337113B1 (en) * | 1999-07-24 | 2002-05-18 | 서경배 | cosmetic composition for promoting the effect of skin-lifting |
JP2002284625A (en) * | 2001-03-23 | 2002-10-03 | Nippon Hypox Lab Inc | Cosmetics |
JP2003104865A (en) * | 2001-07-25 | 2003-04-09 | Noevir Co Ltd | Skin care preparation |
WO2003053327A3 (en) * | 2001-12-20 | 2004-01-15 | Johnson & Johnson Consumer Fr | Compositions containing a retinoid and malt extract |
JP2004532269A (en) * | 2001-06-01 | 2004-10-21 | コグニス・フランス・ソシエテ・アノニム | Cosmetic preparation containing germinated plant extract |
WO2013108513A1 (en) * | 2012-01-17 | 2013-07-25 | 株式会社 資生堂 | Liquid cosmetic |
JP2019026559A (en) * | 2017-07-25 | 2019-02-21 | ピアス株式会社 | Epidermis improver, and external composition for skin |
-
1997
- 1997-08-08 JP JP9227428A patent/JPH1149684A/en active Pending
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100337113B1 (en) * | 1999-07-24 | 2002-05-18 | 서경배 | cosmetic composition for promoting the effect of skin-lifting |
KR20010092070A (en) * | 2000-03-20 | 2001-10-24 | 유상옥,송운한 | Skin elasticity-improving cosmetic composition comprising Chestnut inner bark extract and Malt extract |
JP2002097149A (en) * | 2000-09-20 | 2002-04-02 | Noevir Co Ltd | Skin care preparation |
JP2002104952A (en) * | 2000-09-28 | 2002-04-10 | Noevir Co Ltd | Skin case preparation |
JP2002284625A (en) * | 2001-03-23 | 2002-10-03 | Nippon Hypox Lab Inc | Cosmetics |
JP2004532269A (en) * | 2001-06-01 | 2004-10-21 | コグニス・フランス・ソシエテ・アノニム | Cosmetic preparation containing germinated plant extract |
JP2003104865A (en) * | 2001-07-25 | 2003-04-09 | Noevir Co Ltd | Skin care preparation |
WO2003053327A3 (en) * | 2001-12-20 | 2004-01-15 | Johnson & Johnson Consumer Fr | Compositions containing a retinoid and malt extract |
WO2013108513A1 (en) * | 2012-01-17 | 2013-07-25 | 株式会社 資生堂 | Liquid cosmetic |
JP2013147434A (en) * | 2012-01-17 | 2013-08-01 | Shiseido Co Ltd | Liquid cosmetic |
US9757322B2 (en) | 2012-01-17 | 2017-09-12 | Shiseido Company, Ltd. | Liquid cosmetic |
JP2019026559A (en) * | 2017-07-25 | 2019-02-21 | ピアス株式会社 | Epidermis improver, and external composition for skin |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3696271B2 (en) | Whitening cosmetics | |
DE69313073T2 (en) | LANOLIN FATTY ACID, YOUR SEPARATION, AND COSMETIC AND EXTERNAL APPLICATION | |
JPH1149684A (en) | Climacteric skin lotion | |
JP3448669B2 (en) | Lanolin fatty acid esters, cosmetics and external medicine | |
JP3513872B2 (en) | External preparation for skin | |
JPS6379809A (en) | Skin drug for external use | |
JPH1025236A (en) | Agent for improving and reinforcing nonuniformity of skin and cosmetic containing the same | |
EP1566170B1 (en) | Product for skin care containing ursolic acid and gingko extract | |
JP2000109417A5 (en) | ||
JPH04117318A (en) | Cutaneous amelioration agent | |
JP3444329B2 (en) | Water-in-oil emulsion composition | |
JP4540967B2 (en) | NMF production promoter | |
JPS63290809A (en) | Cosmetic for lip | |
JPH11199463A (en) | Skin cosmetic | |
JP2021066725A (en) | Topical skin preparation | |
JPH1036216A (en) | Skin cosmetic | |
JP2001253817A (en) | Collagen synthesis promoter and method for producing the same and skin care preparation containing the same | |
JP2000143491A (en) | Cosmetic for caring aging | |
KR101154501B1 (en) | A composition of eliminating keratin comprising saussurea involucratae extract | |
WO2019233158A1 (en) | Traditional chinese medicine gel composition, preparation method and use thereof | |
JPH11302147A (en) | Cosmetic | |
JP2755783B2 (en) | Cosmetics | |
JP3822517B2 (en) | Topical skin preparation | |
JPH0797312A (en) | Cosmetic | |
JP3187604B2 (en) | Cosmetics |